7 active not recruiting. 7 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Active not recruiting 7 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Psoriasis: new trials by email Literature Review of Psoriasis trials Research Report on Psoriasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of HSK44459 Cream for the Management Plaque Psoriasis HSK44459 Cream, Vehicle - Psoriasis | Phase 1 / Phase 2 | Active not recruiting | Haisco Pharmaceutical Group Co., Ltd. | 180 | 2026-05-22 | 2026-06-08 |
| Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015) Tulisokibart, Placebo - Psoriatic Arthritis | Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 140 | 2026-04-20 | 2026-10-20 |
| A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis JNJ-88545223, Placebo - Arthritis, Psoriatic | Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 157 | 2026-01-15 | 2026-11-03 |
| Oral and Topical Phytocannabinoids for Psoriasis Oral Cannabis Extract, Topical cannabis cream - Psoriasis Vulgaris | Phase 2 | Active not recruiting | Federal University of Latin American Integration | 37 | 2025-11-01 | 2026-09-24 |
| A Study of SPY072 in Rheumatic Disease SPY002-072, Placebo - Rheumatoid Arthritis, Psoriatic Arthritis | Phase 2 | Active not recruiting | Spyre Therapeutics, Inc. | 285 | 2025-08-21 | 2026-06-05 |
| A Herbal Compound for Psoriasis ZAX.1400.P03, Placebo - Psoriasis, Inflammation | Phase 2 | Active not recruiting | Fasa University of Medical Sciences | 104 | 2023-02-01 | 2025-03-12 |
| Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study Spesolimab - Generalized Pustular Psoriasis | Phase 2 | Active not recruiting | LEO Pharma | 131 | 2019-05-29 | 2026-09-01 |
Arthritis, Psoriatic (3) · Inflammation (2) · Arthritis, Rheumatoid (1) · Axial Spondyloarthritis (1) · Collagen Diseases (1) · Marijuana Abuse (1) · Rheumatic Diseases (1) · Skin Diseases (1)
Skin Diseases, Papulosquamous (7) · Skin and Connective Tissue Diseases (7) · Skin Diseases (6) · Arthritis (3) · Bone Diseases (3) · Joint Diseases (3) · Musculoskeletal Diseases (3) · Spinal Diseases (3) · Spondylarthritis (3) · Spondylarthropathies (3) · Spondylitis (3) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Ankylosis (1)
nabiximols (1) · spesolimab (1)
Fasa University of Medical Sciences (1) · Federal University of Latin American Integration (1) · Haisco Pharmaceutical Group Co., Ltd. (1) · Janssen Research & Development, LLC (1) · LEO Pharma (1) · Merck Sharp & Dohme LLC (1) · Spyre Therapeutics, Inc. (1)
Spain (4) · United States (4) · China (3) · Germany (3) · Poland (3) · Chile (2) · Czechia (2) · Japan (2) · Ukraine (2) · Argentina (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Canada (1) · Colombia (1)
2025 (2), 2018 (1), 2023 (1)